Singapore, Mar 26, 2009: Hard to Treat Diseases (HTDS), a Chinese company focused on the development and licensing of proprietary technologies announced that its subsidiary Mellow Hope was granted registration and licensing approval by Vietnam Food and Drug Administration (FDA).

This license permits Mellow Hope to go directly to the registration of other biological products (with the exception of Hepatitis A Vaccine); a great time-saving vehicle. Two-hundred and fifty vials are scheduled for delivery to Vietnam by the end of March 2009.

Mr Terry Yian CEO of HTDS said, "The Hepatitis A Vaccine (Mevac-A) is a self-owned product in China, with one dose carrying a life-long potency. One-hundred-sixty billion people have received this vaccination over the past fifteen years without any adverse side effects reported to date. The Vietnam population is at considerably high-risk for Hepatitis A. Current market demand is one-million doses, and far exceeds the supply. Once released, the local population will greatly benefit from Mevac-A's superior quality, and a highly competitive price.”